Leukapheresis Market Size, Share & Industry Analysis, By Product Type (Instruments and Consumables), By Procedure Type (Donor Leukapheresis and Therapeutic Leukapheresis), By Technology Platform (Centrifugation, Membrane Filtration, and Others), By End User (Hospitals, Specialty Clinics, Blood Collection Centers & Blood Banks, and Others), and Regional Forecast, 2026-2034

The global leukapheresis market size was valued at USD 621.4 million in 2025 and is projected to grow from USD 665.0 million in 2026 to USD 1,059.3 million by 2034, exhibiting a CAGR of 6.0% during the forecast period.

Leukapheresis is a medical procedure that removes white blood cells from a person’s blood, returning the remaining components, including red cells, plasma, platelets, back into circulation. The procedure plays an essential role in CAR-T cell therapy, stem cell transplantation, and the management of hematological disorders and cancer among patients. The growing prevalence of chronic conditions such as cancer and hematology disorders, rising demand for cell and gene therapies, increasing government initiatives, and expansion of healthcare infrastructure are resulting in a growing adoption rate of these products in the market. The ever-increasing clinical research and biopharmaceutical manufacturing are further contributing to the demand for these procedures in the market.

• For instance, according to 2025 data published by the National Cancer Institute (NCI), about 2.0 million new cancer cases were projected in the U.S.

Additionally, the rising research and development activities among the major companies, including Terumo Corporation and Asahi Kasei Medical Co., Ltd., among others, are further contributing to the adoption of these procedures and devices in the market.

Leukapheresis Market Trends

Technological Advancements in Leukapheresis Products to Boost the Demand

There are increasing technological advancements in leukapheresis products, which are shaping the global leukapheresis market. The modern leukapheresis devices are increasingly integrating continuous-flow centrifugation, automated flow control, improved cell separation algorithms, and real-time monitoring capabilities to improve patient safety and collection efficiency. These platforms allow higher yields, shorter procedure times, reduced extracorporeal blood volume, and enhanced consistency.

Furthermore, the companies are emphasizing sterile disposable kits, mobile leukapheresis centers, closed-system processing, and digital features to meet strict regulatory requirements for advanced therapy medicinal products (ATMPs). The incorporation of software-driven interface systems and smart sensors is also supporting professionals to optimize collection parameters based on patient-specific hematologic profiles, thereby boosting the adoption rate of these products in the market. 

• In May 2025, BBG Advanced Therapies launched the first vehicle, a mobile leukapheresis center designed to perform leukapheresis collections of starting materials for cell and gene therapies.

Market Dynamics

Market Drivers

Download Free sample to learn more about this report.

Increasing Prevalence of Chronic Diseases to Drive Market Growth

The growing prevalence of chronic diseases, including various types of cancer, hematology conditions, and others, further supports the increasing demand for therapeutic leukapheresis procedures among the patient population, consequently boosting the demand for leukapheresis products in the market.

• For instance, according to 2023 data published by Cancer Research UK, it was reported that around 375,400 people are diagnosed with cancer each year in the UK.

This, along with growing demand for cell-based therapies and precision medicine, is further fueling the adoption rate of these systems in the market. Therefore, the factors above, coupled with the rising focus of major players on investments in research and development activities to launch innovative devices, are expected to drive the adoption rate of these systems, thereby supporting the global leukapheresis market size.

Other Prominent Drivers

• Rapid expansion of CAR-T and cell-based immunotherapies.
• Increasing investments in regenerative medicine and personalized therapies.

Market Restraints

High Cost Associated with Procedure & Advanced Infrastructure to Hinder the Market Growth

The high cost associated with leukapheresis procedures and advanced healthcare systems poses a major restraint for the global market. The establishment of a leukapheresis unit requires significant capital investment in automated apheresis devices, monitoring equipment, sterile disposable kits, and temperature-controlled processing environments.

Additionally, the settings involved in cell and gene therapy collections must comply with strict regulatory standards, which further adds to the financial expenditures. This growing cost of therapeutic leukapheresis and leukopaks is limiting adoption in smaller facilities, reducing expansion in emerging countries, and creating reimbursement pressure even in developed nations.

• For instance, according to data published by the National Center for Biotechnology Information (NCBI) in 2021, the cost of CAR-T therapy, where leukapheresis is the first step, ranges from USD 373,000 to USD 475,000 in the U.S.

Market Opportunities

Expansion of Contract Collection Organizations (CCOs) Create Lucrative Market Opportunity

The rapid expansion of contract collection organizations (CCOs) is creating a lucrative opportunity in the global market. The biopharmaceutical companies are increasingly outsourcing leukapheresis and leukopak collection to specialized third-party providers owing to the growing pipelines for cell and gene therapy clinical trials.

The CCOs provide standardized GMP-compliant collection services, donor screening, cryopreservation, and logistics management, allowing therapy developers to emphasize on manufacturing and commercialization. This expands the addressable base for leukapheresis products and fuels its utilization for therapeutic and research purposes.

• According to 2022 data published by the World Economic Forum, more than 2,000 gene therapies were currently under development worldwide.

Market Challenges

Limited Healthcare Access in Emerging Countries to Challenge the Market Development

The limited healthcare access and underdeveloped healthcare infrastructure in developing countries pose a major challenge in the global market. Leukapheresis procedures require advanced equipment, trained professionals, regulated blood processing environments, and strong cold-chain logistics, all of which are often concentrated in tertiary care centers within developed countries.

Additionally, the limited access to advanced cancer care, stem cell transplantation programs, and cell and gene therapy (CGT) infrastructure in many low- and middle-income countries (LMICs), is further expected to hamper the adoption rate for these procedures in the market.

• For instance, according to 2025 statistics published by the World Health Organization (WHO), about 4.6 billion people were not fully covered by essential health services globally in 2023.

SEGMENTATION ANALYSIS

By Product Type

Increasing Hematopoietic Stem Cell Transplants Led to the Dominance of the Consumables Segment

Based on the product type, the market is classified into instruments and consumables.

To know how our report can help streamline your business, Speak to Analyst

The consumables segment held the largest revenue share in 2025. The growth is owing to the increasing number of hematopoietic stem cell transplants among the patient population, resulting in an increasing adoption of consumables worldwide. This, coupled with the growing emphasis of key companies on launching novel consumables, is further expected to support the global leukapheresis market growth.

• For instance, according to 2020 statistics published by the National Center for Biotechnology Information (NCBI), about 1.5 million hematopoietic cell transplants have been performed globally.

The instruments segment is expected to grow at a CAGR of 5.6% over the forecast period.

By Procedure Type

Increasing Prevalence of Chronic Conditions Led to the Dominance of the Therapeutic Leukapheresis Segment

Based on procedure type, the market is segmented into donor leukapheresis and therapeutic leukapheresis.

The therapeutic leukapheresis segment dominated the global market in 2025 by 60.9% of the share. The growth is owing to the increasing incidence and prevalence of leukemia and the growing demand for leukapheresis procedures, supporting the rising demand for donor leukapheresis procedures in the market.

• For instance, according to 2022 statistics published by ScienceDirect, about 20 million new cases were registered globally in 2022.

The segment of donor leukapheresis is set to flourish with a growth rate of 5.8% during the forecast period.

By Technology Platform

Increasing Benefits of Centrifugation-Based Leukapheresis Products Led to the Dominance of the Centrifugation Segment

Based on the technology platform, the market is segmented into centrifugation, membrane filtration, and others.

The centrifugation segment dominated the global market by 88.6% in 2025. The growth is due to the growing benefits of centrifugation-based systems, resulting in the rising adoption of these leukapheresis systems in the market.

• For instance, according to several studies, it was reported that centrifugation-based systems provide increased shelf life, accuracy, and greater purity of the extracted components, more rapid processing of larger blood volumes.

The segment of membrane filtration is set to flourish with a growth rate of 4.5% across the forecast period.

By End-user

Increasing Number of Leukapheresis Procedures Led to the Hospitals Segmental Dominance

Based on end user, the market is divided into hospitals, specialty clinics, blood collection centers & blood banks, and others

The hospitals segment dominated the market in 2025. The increasing number of leukapheresis procedures, rising number of hospitals, among others, are some of the crucial factors contributing to the growth of the segment in the market. Furthermore, the segment is set to hold a 64.1% of the market share in 2026.

• For instance, according to 2025 statistics published by Statistisches Bundesamt, it was reported that there are about 1,874 hospitals in Germany.

In addition, blood collection centers & blood banks segment are projected to grow at a 5.6% CAGR during the forecast period.

Leukapheresis Market Regional Outlook

Based on region, the market has been studied across North America, Europe, Asia Pacific, Latin America, and the Middle East & Africa.

North America

To get more information on the regional analysis of this market, Download Free sample

The North America market held the dominant share in 2024, valued at USD 212.0 billion, and also led the market share in 2025 with USD 228.1 billion. The growing prevalence of chronic conditions such as hematological disorders, and others, high CAR-T adoption, strong reimbursement, growing research applications for leukapheresis, among others, are some of the crucial factors supporting the leukapheresis market share.

• For instance, according to 2022 statistics published by the World Cancer Research Fund (WCRF), about 866,136 new cases of liver cancer were registered globally.

U.S. Leukapheresis Market

Based on North America’s strong contribution and the U.S. dominance within the region, the U.S. market is set to hold a share of USD 221.1 million in 2026, accounting for roughly 35.1% of global sales.

Europe

Europe is projected to record a growth rate of 5.4% in the coming years, which is the second highest among all regions. The region is set to reach a valuation of USD 188.0 million by 2026. The advanced healthcare infrastructure is likely to support the market growth.

U.K Leukapheresis Market

The U.K. market in 2026 is estimated at around USD 34.2 million, representing roughly 5.1% of global revenues.

Germany Leukapheresis Market

Germany’s market is projected to reach approximately USD 47.5 million in 2026, equivalent to around 7.1% of global sales.

Asia Pacific

Asia Pacific is estimated to reach USD 189.8 million in 2026 and secure the position of the third-largest region in the market. The rising cancer burden and the expanding biotech sector are expected to support the growth of the market. In the region, India and China are both estimated to reach USD 24.6 million and USD 54.2 million, respectively, in 2026.

Japan Leukapheresis Market

The Japan market in 2026 is estimated at around USD 47.7 million, accounting for roughly 7.2% of global revenues. Japan has historically reported a relatively high prevalence of various types of cancer and other disorders, with the growing adoption of leukapheresis procedures in the market.

China Leukapheresis Market

China’s market is projected to be one of the largest market shares globally, with 2026 revenues estimated at around USD 54.2 million, representing roughly 8.2% of global sales.

India Leukapheresis Market

The India market size in 2026 is estimated at around USD 24.6 million, accounting for roughly 3.7% of global revenues.

Latin America and Middle East & Africa  

The Latin America and Middle East & Africa regions are expected to witness moderate growth in this market space during the forecast period. The Latin America market is set to reach a valuation of USD 25.3 million in 2026.  The growth is due to the gradual growth in healthcare investments in the region. The Middle East & Africa market is also expected to grow owing to increasing R&D activities among the market players to launch novel products in the market. In the Middle East & Africa, the GCC is set to reach a value of USD 8.4 million in 2026.

South Africa Leukapheresis Market

The South Africa market is projected to reach around USD 3.2 million in 2026, representing roughly 0.5% of global revenues.

Competitive Landscape

Key Industry Players

Increasing Number of Product Launches by Key Industry Players to Support Their Dominance

A significant device portfolio, along with a strong focus on inorganic growth strategies globally, is one of the crucial factors contributing to the dominance of these companies in the market. Terumo Corporation and Asahi Kasei Medical Co., Ltd., are major companies in the market in 2025. Moreover, the growing focus of key companies on product introduction is likely to strengthen their product channel, further supporting the global market share.

• For instance, in October 2019, Terumo Corporation launched the Finia Fill and Finish System, a device developed to help bring reproducibility and cater to the growing demand among the patient population.

Other key players, including Haemonetics Corporation and others, are also growing in the market, primarily due to their increasing focus on mergers and collaborations among other players to strengthen their brand presence in the market.

List of Key Leukapheresis Companies Profiled in the Report

• Fresenius SE & Co. KGaA (Germany)
• Haemonetics Corporation (U.S.)
• Terumo Corporation (Japan)
• Asahi Kasei Medical Co., Ltd. (Japan)
• Lonza (Switzerland)
• Charles River Laboratories (U.S.)
• AllCells (U.S.)
• STEMCELL Technologies (Canada)
• Miltenyi Biotec (Germany)
• Macopharma (France)

KEY INDUSTRY DEVELOPMENTS

• February 2026: BBG Advanced Therapies, an organization in South Texas Blood & Tissue, launched the mobile cell therapy collection vehicle to expand access to next-generation treatments among patients. This helped the company to strengthen its presence.
• January 2026: Fresenius SE & Co. KGaA collaborated with TQ Therapeutics to support the scalable and efficient manufacturing of cell and gene therapies, strengthening its role in advancing next-generation treatments.
• November 2024: Cryoport, Inc., a global company in supply chain solutions for the life sciences industry, established its newest IntegriCell facility in Belgium with an aim to expand its presence.
• January 2024: Gilead Sciences, Inc., received U.S. FDA approval for a manufacturing process change that reduced manufacturing time for Yescarta (axicabtagene ciloleucel). With this approval, the leukapheresis time, where patients’ T cells are collected, is reduced from 16 days to 14 days.
• May 2023: Akadeum Life Sciences launched a new series of products for cell therapy research and development, enabling direct leukopak human immune cell isolation and T-cell activation/expansion kits in the U.S.
• February 2021: Lonza expanded and launched fully customizable, high-quality cryopreserved Leukopaks to strengthen its product channel.

REPORT COVERAGE

The global leukapheresis market report provides a detailed analysis and focuses on key aspects such as leading companies and market segmentation, including product type, procedure type, technology platform, and end user. Besides this, the global report offers insights into the market growth trends and highlights key industry developments. In addition to the aforementioned factors, the report encompasses several factors that have contributed to the growth and advancement of the market over recent years.

Request for Customization   to gain extensive market insights.

Report Scope & Segmentation